Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSH | P09668 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 4/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844020 | 0.92 | TSHR (0.39) | CTSLCTSSCTSKCTSHACE | |
| SCHEMBL30866232 | 0.91 | ACE (0.44) | CXCR4ACERENEPHA2OPRM1 | |
| SCHEMBL29601625 | 0.89 | CTSL (0.46) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29379105 | 0.87 | ACE (0.47) | ACERENTSHR | |
| SCHEMBL29564518 | 0.86 | APLNR (0.47) | CTSLCTSSCTSKCTSHACE | |
| SCHEMBL30272488 | 0.86 | ACE (0.40) | ACERENEPHA2OPRM1OPRK1 | |
| SCHEMBL5311916 | 0.85 | CXCR4 (0.46) | CXCR4EPHA2 | |
| SCHEMBL5311906 | 0.85 | CXCR4 (0.46) | CXCR4EPHA2 | |
| SCHEMBL9616909 | 0.84 | OPRK1 (0.43) | CXCR4ACERENOPRM1OPRK1 | |
| SCHEMBL11644393 | 0.84 | OPRK1 (0.43) | CXCR4ACERENOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | BCN PEPTIDES, S.A. (ES) | 2025-05-13 | — | — | US | disclosed |
| US-20220135640-A1 | CORTISTATIN OR AN ANALOGUE THEREOF AS A PHARMACEUTICALLY ACTIVE AGENT IN LATENT FORM | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | GHSR, GIPR, GHRHR | CXCR4 190/4885CTSL 630/4885CTSS 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.